• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi, Voluntis ink deal for digital insulin management system for T2D

March 14, 2017 By Sarah Faulkner

Sanofi, Voluntis ink deal for digital insulin management system for T2DSanofi (NYSE:SNY) and Voluntis said today that the groups inked a non-exclusive agreement to bring digital insulin management systems for Type II diabetes to the U.S. and several European countries.

The companies 1st established in alliance in 2011, developing a mobile phone application that was designed to improve decision-making and self-management of patients with Type II diabetes treated with basal insulin.

Sanofi and Voluntis plan to launch pilot programs of the app in the U.S. and select European countries. The app won FDA clearance and CE Mark clearance last year.

“We are delighted to expand our long-standing collaboration with Sanofi,” Voluntis chairman Eric Elliott said in prepared remarks. “This new phase of our partnership with a world leader in diabetes will help us deliver digital titration tools into the hands of providers and their patients. Furthermore, digital therapeutics allow manufacturers and payers to check whether agreed value metrics have been achieved and help to lower costs without compromising on patient outcomes and access. They ensure that prescription medications deliver the effects for which they were brought to market.”

In 2011, Sanofi and Voluntis developed Diabeo, a software to help people with diabetes in France manage their basal-bolus treatment.

“Despite the availability of new medicines for the treatment of diabetes, we see that outcomes are not sufficiently improving and that more than half of patients are not well controlled,” Peter Guenter, Sanofi’s executive VP of diabetes & cardiovascular, added. “With this in mind, Sanofi is focusing on a beyond-the-pill approach. We know that diabetes management is a 24/7 job, and we recognize that the right tools need to be developed to realize better outcomes. The long-term alliance we have with Voluntis will help us to reach that goal.”

Filed Under: Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: Sanofi-Aventis, Voluntis

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS